---
title: "Design comprehensive search strategy for medical literature review on immunotherapy effectiveness. Help me: 1) Build Boolean search strings for PubMed/Embase/Cochrane, 2) Identify relevant MeSH terms, 3) Set up search alerts, 4) Plan gray literature search, 5) Document search strategy for PRISMA reporting"
description: "AI model comparison: Design comprehensive search strategy for medical literature review on immunotherapy effectiveness. H..."
date: 2025-10-15
category: comparison
layout: Clean
tags:
  - ChatGPT
  - Claude
  - Gemini
  - AI Comparison
author: SNEOS Community
head:
  - - meta
    - name: description
      content: "AI model comparison: Design comprehensive search strategy for medical literature review on immunotherapy effectiveness. Help me: 1) Build Boo..."
---

<ChatComparison
  title="Design comprehensive search strategy for medical literature review on immunotherapy effectiveness. Help me: 1) Build Boolean search strings for PubMed/Embase/Cochrane, 2) Identify relevant MeSH terms, 3) Set up search alerts, 4) Plan gray literature search, 5) Document search strategy for PRISMA reporting"
  prompt="Design comprehensive search strategy for medical literature review on immunotherapy effectiveness. Help me: 1) Build Boolean search strings for PubMed/Embase/Cochrane, 2) Identify relevant MeSH terms, 3) Set up search alerts, 4) Plan gray literature search, 5) Document search strategy for PRISMA reporting"
  :responses='{"ChatGPT": "Conducting a medical literature review on immunotherapy effectiveness involves several strategic steps. Below is a comprehensive approach to build your search strategy, including Boolean search strings, identification of relevant MeSH terms, setting up search alerts, planning gray literature searches, and documenting for PRISMA reporting.\n\n### 1) Build Boolean Search Strings for PubMed/Embase/Cochrane\n\n**Core Concepts:**\n- Immunotherapy\n- Effectiveness\n- Cancer (or specific diseases, if applicable)\n\n**Example Search Strings:**\n\n#### PubMed\n\u0060\u0060\u0060plaintext\n(\u0022immunotherapy\u0022 OR \u0022immune therapy\u0022 OR \u0022immune modulation\u0022 OR \u0022checkpoint inhibitors\u0022 OR \u0022CAR T-cell therapy\u0022 OR \u0022monoclonal antibodies\u0022) AND (\u0022effectiveness\u0022 OR \u0022efficacy\u0022 OR \u0022outcome\u0022 OR \u0022response\u0022 OR \u0022survival\u0022) AND (\u0022cancer\u0022 OR \u0022tumor\u0022 OR \u0022neoplasm\u0022)\n\u0060\u0060\u0060\n  \n#### Embase\n\u0060\u0060\u0060plaintext\n(\u0027immunotherapy\u0027 OR \u0027immune therapy\u0027 OR \u0027immune modulation\u0027 OR \u0027checkpoint inhibitors\u0027 OR \u0027car t-cell therapy\u0027 OR \u0027monoclonal antibodies\u0027) AND (\u0027effectiveness\u0027 OR \u0027efficacy\u0027 OR \u0027outcome\u0027 OR \u0027response\u0027 OR \u0027survival\u0027) AND (\u0027cancer\u0027 OR \u0027tumor\u0027 OR \u0027neoplasm\u0027)\n\u0060\u0060\u0060\n\n#### Cochrane Library\n\u0060\u0060\u0060plaintext\n(\u0022immunotherapy\u0022 OR \u0022immune therapy\u0022 OR \u0022immune modulation\u0022 OR \u0022checkpoint inhibitors\u0022 OR \u0022CAR T-cell therapy\u0022 OR \u0022monoclonal antibodies\u0022) AND (\u0022effectiveness\u0022 OR \u0022efficacy\u0022 OR \u0022outcome\u0022 OR \u0022response\u0022 OR \u0022survival\u0022) AND (\u0022cancer\u0022 OR \u0022tumor\u0022 OR \u0022neoplasm\u0022)\n\u0060\u0060\u0060\n\n### 2) Identify Relevant MeSH Terms\nFor your PubMed searches, consider the following Medical Subject Headings (MeSH):\n\n- **Immunotherapy**: \n  - \u0022Immunotherapy\u0022[Mesh]\n  - \u0022Antineoplastic Agents\u0022[Mesh]\n  - \u0022Monoclonal Antibodies\u0022[Mesh]\n  - \u0022Cell-Based Therapy\u0022[Mesh]\n\n- **Effectiveness**: \n  - \u0022Treatment Outcome\u0022[Mesh]\n  - \u0022Efficacy\u0022[Subheading]\n\n- **Cancers**: \n  - \u0022Neoplasms\u0022[Mesh] (or specific cancer types like \u0022Lung Neoplasms\u0022[Mesh], \u0022Melanoma\u0022[Mesh], etc.)\n\n### 3) Set Up Search Alerts\nTo stay current with new research, set up email alerts in your databases (PubMed, Embase, Cochrane):\n\n- **PubMed**: After conducting a search, click on \u0022Create alert\u0022 to receive updates.\n- **Embase**: After conducting a search, use the \u0022Save search\u0022 or \u0022Create alert\u0022 feature.\n- **Cochrane Library**: Create a personal account and set up alerts for new publications matching your search.\n\n### 4) Plan Gray Literature Search\nGray literature includes unpublished studies, reports, and research not indexed in major databases. You can search for gray literature using the following resources:\n\n- **Clinical Trials Registries**: \n  - ClinicalTrials.gov\n  - WHO International Clinical Trials Registry Platform (ICTRP)\n- **Conference Proceedings**: Search for recent abstracts in conferences on oncology/immunotherapy (e.g., ASCO, ESMO).\n- **Institutional Repositories**: Access universities, hospitals, and research institutions for unpublished theses or technical reports.\n- **Government Reports**: Look for reports from agencies like the National Institutes of Health (NIH) or FDA.\n\n### 5) Document Search Strategy for PRISMA Reporting\nWhen documenting your search strategy according to PRISMA guidelines, include the following details:\n\n- **Data Sources**: List of databases searched (PubMed, Embase, Cochrane, etc.)\n- **Search Dates**: The date range of your literature search.\n- **Keywords and Search Strings**: Provide the Boolean strings used for each database.\n- **Filters/Limitations**: Specify any limits applied (e.g., publication year, language, study type).\n- **Results Flow Diagram**: Create a PRISMA flow diagram to illustrate the number of records identified, included, excluded, and reasons for exclusions.\n\n#### Example Documentation\n- **PubMed Search**: \n  - Date: MM/DD/YYYY\n  - Search String: (\u0022immunotherapy\u0022 OR ... )\n  - Results: X articles identified, Y included after screening.\n\nRemember to keep a clear, accurate record of all searches and decisions made during the review process for transparent reporting and reproducibility.", "Claude": "# Comprehensive Search Strategy for Immunotherapy Effectiveness Literature Review\n\n## 1. Boolean Search Strings\n\n### Core Concept Framework\n**Population:** Cancer patients (specify if needed)\n**Intervention:** Immunotherapy\n**Comparator:** Standard treatment/placebo\n**Outcome:** Effectiveness/efficacy\n\n### PubMed Search String\n\n\u0060\u0060\u0060\n(\u0022Immunotherapy\u0022[Mesh] OR \u0022Cancer Vaccines\u0022[Mesh] OR \u0022Immune Checkpoint Inhibitors\u0022[Mesh] OR immunotherap*[tiab] OR immuno-therap*[tiab] OR \u0022checkpoint inhibitor*\u0022[tiab] OR \u0022PD-1\u0022[tiab] OR \u0022PD-L1\u0022[tiab] OR \u0022CTLA-4\u0022[tiab] OR nivolumab[tiab] OR pembrolizumab[tiab] OR ipilimumab[tiab] OR atezolizumab[tiab] OR durvalumab[tiab] OR \u0022CAR-T\u0022[tiab] OR \u0022chimeric antigen receptor\u0022[tiab] OR \u0022adoptive cell transfer\u0022[tiab] OR \u0022tumor infiltrating lymphocyte*\u0022[tiab] OR \u0022cancer vaccine*\u0022[tiab] OR \u0022oncolytic virus*\u0022[tiab])\n\nAND\n\n(\u0022Neoplasms\u0022[Mesh] OR cancer*[tiab] OR tumor*[tiab] OR tumour*[tiab] OR malignan*[tiab] OR carcinoma*[tiab] OR neoplasm*[tiab] OR oncolog*[tiab])\n\nAND\n\n(\u0022Treatment Outcome\u0022[Mesh] OR \u0022Survival\u0022[Mesh] OR \u0022Survival Rate\u0022[Mesh] OR \u0022Progression-Free Survival\u0022[Mesh] OR \u0022Overall Survival\u0022[Mesh] OR effectiveness[tiab] OR efficacy[tiab] OR \u0022response rate*\u0022[tiab] OR \u0022overall survival\u0022[tiab] OR \u0022progression free survival\u0022[tiab] OR \u0022disease free survival\u0022[tiab] OR \u0022treatment response\u0022[tiab] OR \u0022clinical outcome*\u0022[tiab] OR \u0022therapeutic effect*\u0022[tiab])\n\nFilters:\n- Publication date: [specify range]\n- Language: English\n- Article types: Clinical Trial, Randomized Controlled Trial, Meta-Analysis, Systematic Review, Comparative Study\n\u0060\u0060\u0060\n\n### Embase Search String (Emtree)\n\n\u0060\u0060\u0060\n(\u0027cancer immunotherapy\u0027/exp OR \u0027immune checkpoint inhibitor\u0027/exp OR \u0027cancer vaccine\u0027/exp OR immunotherap*:ab,ti OR \u0027checkpoint inhibitor*\u0027:ab,ti OR \u0027PD-1\u0027:ab,ti OR \u0027PD-L1\u0027:ab,ti OR \u0027CTLA-4\u0027:ab,ti OR nivolumab/exp OR pembrolizumab/exp OR ipilimumab/exp OR atezolizumab/exp OR \u0027CAR-T cell*\u0027:ab,ti OR \u0027chimeric antigen receptor\u0027:ab,ti OR \u0027adoptive immunotherapy\u0027/exp OR \u0027cancer vaccine*\u0027:ab,ti OR \u0027oncolytic virus\u0027/exp)\n\nAND\n\n(\u0027neoplasm\u0027/exp OR cancer*:ab,ti OR tumor*:ab,ti OR tumour*:ab,ti OR malignan*:ab,ti OR carcinoma*:ab,ti OR neoplasm*:ab,ti)\n\nAND\n\n(\u0027treatment outcome\u0027/exp OR \u0027survival\u0027/exp OR \u0027overall survival\u0027/exp OR \u0027progression free survival\u0027/exp OR effectiveness:ab,ti OR efficacy:ab,ti OR \u0027response rate*\u0027:ab,ti OR \u0027treatment response\u0027:ab,ti OR \u0027clinical outcome*\u0027:ab,ti OR \u0027therapeutic effect*\u0027:ab,ti)\n\nAND\n\n[embase]/lim NOT [medline]/lim\n\nLimits:\n- Human studies\n- English language\n- [Date range]\n\u0060\u0060\u0060\n\n### Cochrane Library Search String\n\n\u0060\u0060\u0060\n#1 MeSH descriptor: [Immunotherapy] explode all trees\n#2 MeSH descriptor: [Immune Checkpoint Inhibitors] explode all trees\n#3 MeSH descriptor: [Cancer Vaccines] explode all trees\n#4 (immunotherap* OR \u0022checkpoint inhibitor*\u0022 OR \u0022PD-1\u0022 OR \u0022PD-L1\u0022 OR \u0022CTLA-4\u0022 OR nivolumab OR pembrolizumab OR", "Gemini": "This is an excellent goal! Designing a comprehensive search strategy is crucial for the rigor and reproducibility of any medical literature review, especially for PRISMA reporting. Immunotherapy is a broad and rapidly evolving field, so a detailed strategy is essential.\n\nLet\u0027s break down the process step-by-step.\n\n---\n\n## Comprehensive Search Strategy for Immunotherapy Effectiveness Literature Review\n\n**Research Question (Example - you will need to refine this for your specific review):**\n\u0022What is the effectiveness of various immunotherapies in adult patients with solid tumors, compared to conventional treatments or placebo, in terms of overall survival, progression-free survival, and objective response rates?\u0022\n\n*Self-correction: If your review is *not* limited to solid tumors, remove that qualifier. If it\u0027s *not* limited to adults, remove that. If you are interested in a specific cancer type (e.g., melanoma), replace \u0022solid tumors\u0022 with \u0022melanoma\u0022. This example provides a good starting point.*\n\n---\n\n### 1. Identify Core Concepts \u0026 Keywords\n\nBased on the example research question, the core concepts are:\n\n*   **P (Population):** Adult patients, Solid tumors (or specific cancer type)\n*   **I (Intervention):** Immunotherapy (broad), Specific immunotherapy types\n*   **C (Comparison):** Conventional treatments, Placebo (often implicit, or handled by study design)\n*   **O (Outcome):** Effectiveness, Overall Survival (OS), Progression-Free Survival (PFS), Objective Response Rate (ORR), Efficacy, Treatment outcome\n\nFrom these, we\u0027ll extract keywords and MeSH/Emtree terms.\n\n---\n\n### 2. Identify Relevant MeSH Terms (PubMed/Cochrane) \u0026 Emtree Terms (Embase)\n\nThis step is critical. MeSH (Medical Subject Headings) and Emtree are controlled vocabularies that allow for precise and comprehensive searching. Always explore the MeSH/Emtree trees to find broader and narrower terms.\n\n**Concept 1: Immunotherapy (Broad \u0026 Specifics)**\n*   **MeSH:**\n    *   \u0022Immunotherapy\u0022\n    *   \u0022Adoptive Immunotherapy\u0022 (covers CAR T-cell, TILs, etc.)\n    *   \u0022Checkpoint Inhibitors\u0022\n    *   \u0022Chimeric Antigen Receptor T-Cells\u0022 (CAR T-cells)\n    *   \u0022Oncolytic Viruses\u0022\n    *   \u0022Cancer Vaccines\u0022 (for therapeutic vaccines)\n    *   \u0022Cytokines\u0022 (e.g., Interleukins, Interferons - if relevant to your scope)\n    *   \u0022Immunoactive Agents\u0022\n*   **Emtree (Embase - often overlaps, but also more drug-specific):**\n    *   \u0027immunotherapy\u0027/exp (explodes to narrower terms)\n    *   \u0027checkpoint inhibitor\u0027\n    *   \u0027PD-1 inhibitor\u0027\n    *   \u0027PD-L1 inhibitor\u0027\n    *   \u0027CTLA-4 inhibitor\u0027\n    *   \u0027chimeric antigen receptor T cell\u0027\n    *   \u0027oncolytic virus\u0027\n    *   \u0027cancer vaccine\u0027\n    *   \u0027cytokine\u0027\n    *   \u0027immunomodulating agent\u0027\n\n**Concept 2: Effectiveness/Outcome**\n*   **MeSH:**\n    *   \u0022Treatment Outcome\u0022\n    *   \u0022Survival Rate\u0022\n    *   \u0022Disease-Free Survival\u0022\n    *   \u0022Progression-Free Survival\u0022\n    *   \u0022Response Rate\u0022 (often within \u0022Treatment Outcome\u0022 but can be keyworded)\n    *   \u0022Clinical Benefit\u0022 (keyword)\n*   **Emtree:**\n    *   \u0027treatment outcome\u0027/exp\n    *   \u0027survival\u0027\n    *   \u0027disease free survival\u0027\n    *   \u0027progression free survival\u0027\n    *   \u0027remission\u0027\n    *   \u0027drug efficacy\u0027\n\n**Concept 3: Population/Disease (Example: Solid Tumors)**\n*   **MeSH:**\n    *   \u0022Neoplasms\u0022 (broad)\n    *   \u0022Solid Tumors\u0022 (no direct MeSH, use \u0022Neoplasms\u0022 and keywords, or specific tumor MeSH)\n    *   Specific MeSH for tumor types if applicable (e.g., \u0022Melanoma\u0022, \u0022Lung Neoplasms\u0022, \u0022Breast Neoplasms\u0022, \u0022Colorectal Neoplasms\u0022)\n*   **Emtree:**\n    *   \u0027cancer\u0027/exp\n    *   \u0027tumor\u0027/exp\n    *   Specific Emtree terms (e.g., \u0027melanoma\u0027, \u0027lung cancer\u0027)\n\n---\n\n### 3. Build Boolean Search Strings (PubMed, Embase, Cochrane)\n\n**General Strategy for each database:**\n\u0060(Concept 1: Immunotherapy OR Specific Agents) AND (Concept 2: Effectiveness/Outcomes) AND (Concept 3: Population/Disease - *optional, depending on breadth*)\u0060\n\n**Important Notes:**\n*   \u0060*\u0060 (truncation) captures variations (e.g., \u0060therap*\u0060 finds therapy, therapies, therapeutic).\n*   \u0060\u0022\u0060 (phrase searching) ensures words are searched together (e.g., \u0060\u0022CAR T-cell\u0022\u0060).\n*   Always test individual terms and combinations.\n*   The \u0060[Mesh]\u0060 tag in PubMed automatically explodes the term unless \u0060[MeSH:noexp]\u0060 is used. Default for Emtree is also explosion with \u0060/exp\u0060.\n\n---\n\n#### 3.1 PubMed Search String\n\n\u0060\u0060\u0060\n(\n  (\u0022Immunotherapy\u0022[Mesh] OR \u0022Adoptive Immunotherapy\u0022[Mesh] OR \u0022Checkpoint Inhibitors\u0022[Mesh] OR \u0022Chimeric Antigen Receptor T-Cells\u0022[Mesh] OR \u0022Oncolytic Viruses\u0022[Mesh] OR \u0022Cancer Vaccines\u0022[Mesh] OR \u0022Cytokines\u0022[Mesh])\n  OR\n  (immunotherap* OR \u0022immune therap*\u0022 OR \u0022immunologic agent*\u0022 OR \u0022immunomodulat*\u0022 OR \u0022immune check point inhibitor*\u0022 OR \u0022PD-1 inhibitor*\u0022 OR \u0022PDL1 inhibitor*\u0022 OR \u0022CTLA-4 inhibitor*\u0022 OR \u0022CAR T-cell*\u0022 OR \u0022chimeric antigen receptor T cell*\u0022 OR \u0022oncolytic virus*\u0022 OR \u0022therapeutic vaccine*\u0022 OR \u0022cytokine therap*\u0022 OR interleukin OR interferon OR nivolumab OR pembrolizumab OR atezolizumab OR durvalumab OR avelumab OR ipilimumab OR tremelimumab OR t-vec OR tisagenlecleucel OR axicabtagene OR brexucabtagene)\n)\nAND\n(\n  (\u0022Treatment Outcome\u0022[Mesh] OR \u0022Survival Rate\u0022[Mesh] OR \u0022Disease-Free Survival\u0022[Mesh] OR \u0022Progression-Free Survival\u0022[Mesh])\n  OR\n  (effectiv* OR efficac* OR outcome* OR survival OR response OR remission OR prognostic* OR \u0022disease control\u0022 OR \u0022clinical benefit\u0022 OR \u0022treatment response\u0022 OR \u0022overall survival\u0022 OR \u0022progression-free survival\u0022 OR \u0022objective response rate\u0022)\n)\nAND\n(\n  (\u0022Neoplasms\u0022[Mesh])\n  OR\n  (cancer OR neoplasm* OR carcinoma* OR tumor* OR malignanc* OR \u0022solid tumor*\u0022)\n)\nAND humans[Filter] AND english[Filter]\n\u0060\u0060\u0060\n**Explanation:**\n*   Combines broad MeSH terms with specific keywords and common drug names.\n*   Effectiveness concepts include MeSH and keywords.\n*   Disease concept is broad for \u0022Neoplasms\u0022 and keywords.\n*   \u0060AND humans[Filter] AND english[Filter]\u0060 are standard filters. You might also add \u0060(\u0022clinical trial\u0022[Publication Type] OR \u0022randomized controlled trial\u0022[Publication Type] OR \u0022systematic review\u0022[Publication Type] OR \u0022meta-analysis\u0022[Publication Type])\u0060 if you want to narrow by study design *within* PubMed.\n\n---\n\n#### 3.2 Embase Search String (Ovid platform example - adapt for Embase.com)\n\n\u0060\u0060\u0060\n(\n  (immunotherapy/exp OR \u0027checkpoint inhibitor\u0027/exp OR \u0027chimeric antigen receptor T cell\u0027/exp OR \u0027oncolytic virus\u0027/exp OR \u0027cancer vaccine\u0027/exp OR cytokine/exp OR \u0027immunomodulating agent\u0027/exp)\n  OR\n  (immunotherap* OR \u0027immune therap*\u0027 OR \u0027immunologic agent*\u0027 OR immunomodulat* OR \u0027immune check point inhibitor*\u0027 OR \u0027PD-1 inhibitor*\u0027 OR \u0027PDL1 inhibitor*\u0027 OR \u0027CTLA-4 inhibitor*\u0027 OR \u0027CAR T-cell*\u0027 OR \u0027chimeric antigen receptor T cell*\u0027 OR \u0027oncolytic virus*\u0027 OR \u0027therapeutic vaccine*\u0027 OR \u0027cytokine therap*\u0027 OR interleukin OR interferon OR nivolumab OR pembrolizumab OR atezolizumab OR durvalumab OR avelumab OR ipilimumab OR tremelimumab OR t-vec OR tisagenlecleucel OR axicabtagene OR brexucabtagene).ti,ab.\n)\nAND\n(\n  (treatment outcome/exp OR survival/exp OR \u0027disease free survival\u0027/exp OR \u0027progression free survival\u0027/exp OR \u0027drug efficacy\u0027/exp)\n  OR\n  (effectiv* OR efficac* OR outcome* OR survival OR response OR remission OR prognostic* OR \u0027disease control\u0027 OR \u0027clinical benefit\u0027 OR \u0027treatment response\u0027 OR \u0027overall survival\u0027 OR \u0027progression-free survival\u0027 OR \u0027objective response rate\u0027).ti,ab.\n)\nAND\n(\n  (cancer/exp OR tumor/exp OR neoplasm/exp)\n  OR\n  (cancer OR neoplasm* OR carcinoma* OR tumor* OR malignanc* OR \u0027solid tumor*\u0027).ti,ab.\n)\nAND (human/de) AND (english/la)\n\u0060\u0060\u0060\n**Explanation:**\n*   \u0060\u0027/exp\u0027\u0060 is used for Emtree term explosion.\n*   \u0060.ti,ab.\u0060 targets terms in title and abstract. You can use \u0060.mp.\u0060 for \u0022multi-purpose\u0022 (which includes title, abstract, original title, drug trade name, etc.).\n*   \u0060(human/de)\u0060 and \u0060(english/la)\u0060 are typical Ovid filters for human and English language.\n*   Embase is excellent for drug names and adverse events, so consider if your review needs to delve deeper into specific agents.\n\n---\n\n#### 3.3 Cochrane Library Search String (CENTRAL - Cochrane Register of Controlled Trials)\n\nCochrane Central is primarily for identifying randomized controlled trials. It uses a simplified search interface compared to PubMed/Embase. You can often use MeSH terms directly or keywords.\n\n**Approach 1: Using their Advanced Search Builder**\n*   **Step 1 (Immunotherapy):**\n    *   MeSH terms: \u0060(\u0022Immunotherapy\u0022 OR \u0022Checkpoint Inhibitors\u0022 OR \u0022Chimeric Antigen Receptor T-Cells\u0022 OR \u0022Cancer Vaccines\u0022 OR \u0022Oncolytic Viruses\u0022)\u0060\n    *   Keywords (Title/Abstract): \u0060(immunotherap* OR \u0022immune therap*\u0022 OR \u0022CAR T\u0022 OR \u0022PD-1\u0022 OR \u0022PDL1\u0022 OR \u0022CTLA-4\u0022 OR nivolumab OR pembrolizumab OR \u0022oncolytic virus*\u0022)\u0060\n    *   Combine these with OR.\n*   **Step 2 (Effectiveness/Outcome):**\n    *   MeSH terms: \u0060(\u0022Treatment Outcome\u0022 OR \u0022Survival Rate\u0022 OR \u0022Progression-Free Survival\u0022)\u0060\n    *   Keywords (Title/Abstract): \u0060(effectiv* OR efficac* OR survival OR response OR \u0022disease control\u0022)\u0060\n    *   Combine these with OR.\n*   **Step 3 (Disease - if specified):**\n    *   MeSH terms: \u0060(\u0022Neoplasms\u0022)\u0060\n    *   Keywords (Title/Abstract): \u0060(cancer OR neoplasm* OR tumor*)\u0060\n    *   Combine these with OR.\n*   **Step 4: Combine all three steps with AND.**\n\n**Approach 2: Example combined string for CENTRAL (less precise field tagging than PubMed/Embase):**\n\n\u0060\u0060\u0060\n(immunotherap* OR \u0022immune therap*\u0022 OR \u0022immunologic agent*\u0022 OR \u0022immunomodulat*\u0022 OR \u0022checkpoint inhibitor*\u0022 OR \u0022PD-1\u0022 OR \u0022PDL1\u0022 OR \u0022CTLA-4\u0022 OR \u0022CAR T-cell*\u0022 OR \u0022chimeric antigen receptor*\u0022 OR \u0022oncolytic virus*\u0022 OR \u0022therapeutic vaccine*\u0022 OR \u0022cytokine therap*\u0022 OR nivolumab OR pembrolizumab OR atezolizumab OR durvalumab OR avelumab OR ipilimumab OR tremelimumab OR t-vec OR tisagenlecleucel OR axicabtagene OR brexucabtagene OR MeSH descriptor: [Immunotherapy] OR MeSH descriptor: [Checkpoint Inhibitors] OR MeSH descriptor: [Chimeric Antigen Receptor T-Cells] OR MeSH descriptor: [Oncolytic Viruses] OR MeSH descriptor: [Cancer Vaccines] OR MeSH descriptor: [Cytokines])\n\nAND\n\n(effectiv* OR efficac* OR outcome* OR survival OR response OR remission OR prognostic* OR \u0022disease control\u0022 OR \u0022clinical benefit\u0022 OR \u0022treatment response\u0022 OR \u0022overall survival\u0022 OR \u0022progression-free survival\u0022 OR \u0022objective response rate\u0022 OR MeSH descriptor: [Treatment Outcome] OR MeSH descriptor: [Survival Rate] OR MeSH descriptor: [Disease-Free Survival] OR MeSH descriptor: [Progression-Free Survival])\n\nAND\n\n(cancer OR neoplasm* OR carcinoma* OR tumor* OR malignanc* OR \u0022solid tumor*\u0022 OR MeSH descriptor: [Neoplasms])\n\n\u0060\u0060\u0060\n**Filters:** Cochrane has built-in filters for study types, dates, etc., which you can apply after running the search.\n\n---\n\n### 4. Set Up Search Alerts\n\nThis is crucial for keeping your review current and capturing new publications during the review process.\n\n*   **PubMed (My NCBI):**\n    1.  Run your final, optimized search query.\n    2.  Click \u0022Create Alert\u0022 or \u0022Save Search\u0022 under the search bar.\n    3.  You\u0027ll be prompted to log in or create a My NCBI account.\n    4.  Configure alert settings: Name your search, choose email frequency (e.g., weekly, monthly), and format.\n*   **Embase (Embase.com or Ovid):**\n    1.  Run your final search query.\n    2.  Look for \u0022Save Search / Alert\u0022 or similar options.\n    3.  For Ovid, click \u0022Save History\u0022 then \u0022AutoAlert\u0022.\n    4.  Configure frequency (weekly, monthly) and email settings.\n*   **Cochrane Library (Wiley Platform):**\n    1.  Run your final search query.\n    2.  Click \u0022Save Search\u0022 or \u0022Create Alert\u0022 (usually a bell icon or similar).\n    3.  Register for a free Wiley Online Library account if you don\u0027t have one.\n    4.  Set up the alert frequency (weekly, monthly).\n*   **Google Scholar:** While not as systematic, a broad alert here can sometimes catch things other databases miss.\n    1.  Go to Google Scholar.\n    2.  Run a simpler version of your search (e.g., \u0060\u0022immunotherapy\u0022 \u0022effectiveness\u0022 \u0022cancer\u0022\u0060).\n    3.  Click the \u0022Create alert\u0022 envelope icon in the left sidebar.\n    4.  Enter your email and create the alert.\n\n**Frequency:** For a rapidly moving field like immunotherapy, \u0060weekly\u0060 alerts are recommended for the core databases (PubMed, Embase, Cochrane) during the active phase of your review. Once screening is complete, you might switch to \u0060monthly\u0060 to monitor for significant updates.\n\n---\n\n### 5. Plan Gray Literature Search\n\nGray literature includes unpublished studies, conference abstracts, clinical trial registries, government reports, and dissertations. It\u0027s essential to reduce publication bias.\n\n*   **Clinical Trial Registries:**\n    *   **ClinicalTrials.gov:** Search for ongoing or completed trials. Use broader terms (e.g., \u0060\u0022immunotherapy\u0022 AND \u0022cancer\u0022\u0060). Look for terms like \u0022completed,\u0022 \u0022active, not recruiting,\u0022 \u0022results available.\u0022\n    *   **EU Clinical Trials Register:** (for trials in Europe)\n    *   **WHO International Clinical Trials Registry Platform (ICTRP):** A portal to multiple national registries.\n*   **Conference Proceedings/Abstracts:**\n    *   **American Society of Clinical Oncology (ASCO):** Access abstracts via their meeting library.\n    *   **European Society for Medical Oncology (ESMO):** Meeting abstracts.\n    *   **American Association for Cancer Research (AACR):** Meeting abstracts.\n    *   **Society for Immunotherapy of Cancer (SITC):** Specific to immunotherapy.\n    *   Search tip: Use the conference websites directly.\n*   **Governmental/Organizational Reports:**\n    *   **National Institutes of Health (NIH), National Cancer Institute (NCI):** Websites for reports, guidelines, ongoing research.\n    *   **World Health Organization (WHO):** Reports and guidelines.\n    *   **National Institute for Health and Care Excellence (NICE), Agency for Healthcare Research and Quality (AHRQ):** For clinical guidelines and evidence reviews.\n*   **Theses and Dissertations:**\n    *   **ProQuest Dissertations \u0026 Theses Global:** A large repository.\n*   **Drug Company Websites:** Major pharmaceutical companies involved in immunotherapy often publish trial data or summaries on their sites (e.g., Merck, BMS, Roche, Novartis). Search directly on their \u0022clinical trials\u0022 or \u0022research\u0022 sections.\n*   **Preprint Servers (Use with caution):**\n    *   **medRxiv, bioRxiv:** Contains non-peer-reviewed manuscripts. Be transparent if you include these and acknowledge their pre-publication status. Generally, it\u0027s better to stick to peer-reviewed for effectiveness reviews unless your scope explicitly includes preliminary findings.\n\n**Strategy for Gray Literature:**\n*   Use simpler, broader search terms (e.g., \u0022immunotherapy cancer effectiveness\u0022) as Boolean logic is often limited.\n*   Filter by date to focus on recent studies.\n*   Hand-search reference lists of included articles (particularly systematic reviews and guidelines) for additional relevant gray literature.\n*   Consider contacting experts in the field for unpublished data if appropriate for your review scope.\n\n---\n\n### 6. Document Search Strategy for PRISMA Reporting\n\nThorough documentation is paramount for PRISMA. Create a detailed log or table.\n\n**Components to Document:**\n\n1.  **Database Names and Platforms:** List all databases searched (e.g., PubMed via NCBI, Embase via Ovid, Cochrane Library via Wiley).\n2.  **Date of Search:** State the full date (e.g., \u0022All databases were searched on September 25, 2023\u0022). If updated, list the update date.\n3.  **Full Search Strings:** Provide the exact, complete Boolean search string for *each* database. This is critical for reproducibility.\n    *   *Self-correction:* Do *not* just provide the concept breakdown; provide the actual query that was entered.\n4.  **Number of Results:** Record the raw number of results retrieved from each database *before* deduplication.\n5.  **Limits/Filters Applied:**\n    *   Language (e.g., \u0022English\u0022)\n    *   Publication Type (e.g., \u0022Clinical Trial,\u0022 \u0022Randomized Controlled Trial,\u0022 \u0022Systematic Review,\u0022 \u0022Meta-Analysis\u0022)\n    *   Date Range (e.g., \u0022from 2010 to present\u0022)\n    *   Human studies (e.g., \u0022human subjects\u0022)\n    *   Any other specific filters (e.g., \u0022adults\u0022)\n6.  **Search Alert Setup:**\n    *   Date alerts were set up.\n    *   Databases for which alerts were created.\n    *   Frequency of alerts (e.g., \u0022weekly\u0022).\n7.  **Gray Literature Sources:**\n    *   List all gray literature sources searched (e.g., ClinicalTrials.gov, ASCO meeting abstracts).\n    *   Dates searched.\n    *   Search terms used (if different from main database strings).\n    *   Number of relevant items identified (if quantifiable).\n8.  **Justification of Choices:** Briefly explain *why* certain terms were chosen, why MeSH/Emtree were exploded, or why specific filters were used.\n    *   *Example:* \u0022MeSH terms were chosen and exploded to ensure comprehensive coverage of both broad and specific immunotherapy concepts and related outcomes.\u0022\n9.  **Librarian Consultation:** State if a medical librarian was consulted for strategy development and optimization. This enhances credibility.\n\n**Example PRISMA Search Documentation Table (Extract):**\n\n| Database (Platform) | Date Last Searched | Full Search String (as entered) | Number of Results | Filters Applied (Language, Date, Study Type, etc.) | Alerts Set |\n| :------------------ | :----------------- | :----------------------------- | :---------------- | :----------------------------------------------- | :-------- |\n| PubMed (NCBI)       | Sept 25, 2023      | \u0060(((\u0022Immunotherapy\u0022[Mesh] OR ... AND humans[Filter] AND english[Filter]\u0060 (full string from 3.1) | 15,487            | English, Human, Publication Date: 2010-present   | Yes (Weekly) |\n| Embase (Ovid)       | Sept 25, 2023      | \u0060((immunotherapy/exp OR ... AND (human/de) AND (english/la)\u0060 (full string from 3.2) | 22,105            | English, Human, Publication Date: 2010-present   | Yes (Weekly) |\n| Cochrane CENTRAL    | Sept 25, 2023      | \u0060(immunotherap* OR ... AND MeSH descriptor: [Neoplasms])\u0060 (full string from 3.3) | 8,920             | English, Publication Date: 2010-present          | Yes (Weekly) |\n| ClinicalTrials.gov  | Sept 26, 2023      | \u0060\u0022immunotherapy\u0022 AND \u0022cancer\u0022\u0060   | 1,250             | Status: Completed/Active, not recruiting; Updated: 2010-present | No        |\n| ASCO Meeting Library| Sept 27, 2023      | \u0060\u0022immunotherapy\u0022 \u0022survival\u0022\u0060     | N/A (manual screen) | 2018-2023 Annual Meetings                        | No        |\n| *... (add others)*  |                    |                                |                   |                                                  |           |\n\n---\n\n### Final Recommendations:\n\n*   **Pilot Testing:** Run your search strings in each database. Review the first 50-100 results to see if they are relevant. Adjust terms if necessary (e.g., if too many irrelevant results, add more specific terms or use \u0060NOT\u0060 for exclusions; if too few, broaden terms or explode more MeSH).\n*   **Librarian Consultation:** Seriously consider collaborating with a medical librarian. They are experts in search strategy design and database specificities.\n*   **Iterative Process:** Search strategy development is iterative. Start broad, refine, test, and then optimize.\n*   **Transparency:** Be completely transparent in your documentation, making it easy for others to replicate your search.\n\nThis comprehensive plan should set you up for a rigorous and PRISMA-compliant literature review on immunotherapy effectiveness. Good luck!"}' published-date="{DateTime.UtcNow:HH:mm}"
/>

## Analysis

This comparison demonstrates the different approaches each AI model takes when responding to the same prompt. Here are the key differences observed:

### Response Characteristics

**ChatGPT**: Provides a detailed response with 25 sentences. 

**Claude**: Provides a detailed response with 1 sentences. 

**Gemini**: Provides a direct response with 220 sentences. 

## Key Takeaways

- Each model brings unique strengths to this type of query
- Response styles vary significantly between models
- Consider your specific use case when choosing between these models

## Try This Comparison Yourself

Want to test these models with your own prompts? Visit [SNEOS.com](https://sneos.com) to compare AI responses side-by-side in real-time.

---

*This comparison was generated using the [SNEOS AI Comparison Tool](https://sneos.com)*
*Published: October 15, 2025 | Models: ChatGPT, Claude, Gemini*
